United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
236 ^USD	-0.44%		-0.41%	+7.30%

Apr. 23	United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	MT
Apr. 23	United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	MT

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of United Therapeutics Corporation (UTHR)

February 26, 2018 at 10:11 am EST

NEW YORK, Feb. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/uthr.

Bronstein, Gewirtz & Grossman, LLC

The investigation concerns whether United Therapeutics and certain of its officers and/or directors have violated federal securities laws.

On February 21, 2018, United Therapeutics revealed that because of an increase in the royalty rate the Company is required to pay Eli Lilly for Adcirca under an amended licensed agreement, its cost of product sales have gone up. Following this news, United Therapeutics stock dropped $17.41 per share or roughly 2.9% over the next two trading days to close at $117.55 on February 22, 2018.

If you are aware of any facts relating to this investigation, or purchased United Therapeutics shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/uthr. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

View original content with multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-united-therapeutics-corporation-uthr-300603997.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Latest news about United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	Apr. 23	MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	Apr. 23	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	Apr. 05	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	Apr. 04	MT
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	Apr. 01	DJ
United Therapeutics Corporation Announces Extension of Credit Agreement	Mar. 29	CI
United Therapeutics Insider Sold Shares Worth $7,375,339, According to a Recent SEC Filing	Mar. 27	MT
United Therapeutics Corporation announces an Equity Buyback for $1,000 million worth of its shares.	Mar. 25	CI
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	Mar. 25	MT
United Therapeutics Authorizes Accelerated $1 Billion Stock Buyback Through Citigroup	Mar. 25	MT
United Therapeutics Corporation authorizes a Buyback Plan.	Mar. 23	CI
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	Mar. 22	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	Mar. 21	MT
United Therapeutics Insider Sold Shares Worth $7,209,192, According to a Recent SEC Filing	Mar. 15	MT
Transcript : United Therapeutics Corporation Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 01:40 PM	Mar. 12
United Therapeutics Insider Sold Shares Worth $7,232,241, According to a Recent SEC Filing	Mar. 11	MT
United Therapeutics Insider Sold Shares Worth $1,424,309, According to a Recent SEC Filing	Mar. 07	MT
United Therapeutics Insider Sold Shares Worth $3,705,423, According to a Recent SEC Filing	Mar. 05	MT
Transcript : United Therapeutics Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM	Mar. 05

Chart United Therapeutics Corporation

Duration

Period

More charts

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

236 USD

Average target price

285.5 USD

Spread / Average Target

+20.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
BIO-TECHNE CORPORATION	-18.79%	9.98B

Other Biotechnology & Medical Research